InTest Secures $3.7M Order to Expand Medical Device Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- Order Expansion: InTest Corporation has secured a follow-on $3.7 million order from an existing customer, aimed at providing additional functional test systems for medical device manufacturers, thereby enhancing its market presence in the life sciences sector.
- Automated Testing Solutions: Alfamation will supply multiple conveyor-based testing systems equipped with high-precision instruments and fixtures, which will enhance testing efficiency and support the testing of 50 million devices annually, significantly increasing production capacity.
- Critical Technical Capability: This order highlights Alfamation's expertise in performing high-performance electrical measurements at the PCB level, which is crucial for products that cannot be evaluated when fully assembled, ensuring the safety and effectiveness of medical devices.
- Strategic Growth: InTest's growth strategy is further validated by this order, indicating that its expansion into the medical device sector relies not only on technological innovation but also on organic growth through acquisitions and market penetration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INTT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INTT
Wall Street analysts forecast INTT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTT is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 9.350
Low
10.00
Averages
10.00
High
10.00
Current: 9.350
Low
10.00
Averages
10.00
High
10.00
About INTT
inTEST Corporation is a global supplier of test and process technology solutions for use in manufacturing and testing in key target markets. Its segments include Electronic Test, Environmental Technologies and Process Technologies. The Electronic Test segment consists of inTEST EMS, which has operations in New Jersey and California, and Acculogic, which has operations in Canada, California and Germany, and Alfamation S.p.A., which has operations in Italy and China. The Environmental Technologies segment consists of inTEST Thermal Solutions (iTS), which manufactures and sells products under the Temptronic, Sigma, Thermonics and North Sciences brand names and has operations in Massachusetts, Germany and Singapore. The Process Technologies segment consists of Ambrell and Videology. Ambrell provides customers with induction heating solutions for a wide variety of manufacturing processes. Videology is a designer, developer and manufacturer of digital streaming and image-capturing solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
inTest Corporation (INTT) Shares Surge 8.9% Amid Record Order Growth
- Stock Performance: inTest Corporation's shares rallied 8.9% in the last trading session to close at $8.72, with notable trading volume indicating strong market confidence in its future performance.
- Order Growth: The company is benefiting from record order growth and robust demand in the auto, EV, and defense sectors, supporting expectations for a gradual recovery, despite a quarterly EPS estimate of $0.16, reflecting a 30.4% year-over-year decline.
- Revenue Expectations: Expected revenues of $31.74 million represent a 13.3% decline from the previous year, yet optimism remains due to successful new product adoption and higher conversion rates, which may drive future growth.
- Analyst Rating: Currently holding a Zacks Rank of #3 (Hold), inTest's stock may struggle to maintain upward momentum in the absence of earnings estimate revisions, prompting investors to closely monitor upcoming developments.
Continue Reading
InTest CEO to Participate in 14th Annual NYC Summit
- Executive Participation: InTest's President and CEO Nick Grant, along with CFO Duncan Gilmour, will attend the 14th Annual NYC Summit on December 16, 2025, at Mastro's Steakhouse in New York, showcasing the company's innovative technologies in key markets such as semiconductors, automotive, and life sciences.
- Investor Engagement: The summit will feature a
Continue Reading